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ABSTRACT
Background: Hypertension and type 2 diabetes
mellitus (T2DM) synergistically deteriorate the
vascular environment, making blood pressure
reduction challenging, and substantially
increasing cardiovascular risk.
Methods: In the real-life, open-label,
observational, PICASSO study, 9,257
hypertensive patients unsuccessfully treated
with antihypertensives were switched to fixed-
dose combination of perindopril 10 mg/
indapamide 2.5 mg. In this subgroup analysis,
we analyzed changes in blood pressure and
laboratory parameters of 2,762 hypertensive
patients with T2DM or pre-diabetes.
Results: After 3 months of treatment,
significant decreases in office blood
pressure were noted in the whole cohort
(-27.0 ± 14.8/-12.7 ± 9.8 mmHg; p\0.001).
Significant decreases were also recorded
in patients with grade 1 hypertension
(19.2 ± 10.0/-9.4 ± 7.9 mmHg), grade 2
(29.2 ± 10.9/-13.3 ± 8.7 mmHg) and grade 3
(-45.1 ± 15.4/-21.5 ± 11.2 mmHg). Significant
decreases in ambulatory blood pressure were
also noted (n = 93). In patients previously
treated with angiotensin-converting
enzyme inhibitor ± hydrochlorothiazide or
angiotensin receptor blocker ±
hydrochlorothiazide, mean 24-h blood
pressure decreased by 23.4 ± 13.9/
11.5 ± 9.7 and 22.3 ± 8.7/10.4 ± 13.2 mmHg,
respectively (p\0.001). Treatment was well
tolerated and the switch to treatment with
perindopril/indapamide was associated with
improvements in laboratory parameters.
Conclusions: Data from this diabetes
subgroup analysis suggest that fixed
combination of perindopril 10 mg/
indapamide 2.5 mg should be routinely
considered for the treatment of hypertension
in diabetic patients who are unsuccessfully
managed with other antihypertensive
medications.
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INTRODUCTION
Recent epidemiologic data underscore the
ongoing difficulties associated with reducing
blood pressure in diabetic hypertensive patients
[1, 2]. Analysis of the International Survey
Evaluating Microalbuminuria Routinely by
Cardiologists in Patients with Hypertension
(I-SEARCH) survey, for example, showed that
blood pressure control rates in diabetic patients
were very low with only 19% of men and 16%
of women reaching control, even though 93.5%
of patients in the whole cohort were being
treated and most diabetic patients were taking
between two and three drugs [2]. These data
suggest that the problem with blood pressure
control in diabetic patients is no longer lack of
treatment and that our focus needs to turn
toward improving treatment strategies.
For hypertensive patients with type 2
diabetes mellitus (T2DM), recent European
guidelines [European Society of Hypertension
(ESH)/European Society of Cardiology (ESC)
2013] recommend that combination
treatments, preferably fixed-dose
combinations, be considered and that
treatments include renin–angiotensin–
aldosterone system (RAS) inhibitors to protect
the diabetic kidney from nephropathy [3]. In
line with guidelines, combination treatment
with perindopril/indapamide is well suited for
the treatment of diabetic patients: perindopril is
a long-acting angiotensin-converting enzyme
(ACE) inhibitor that has been proven to be
nephroprotective [4] and indapamide is a
metabolically neutral diuretic with mild
natriuretic effects [5]. Treatment with
perindopril/indapamide is also supported by
extensive data from clinical trials [4, 6–11] and
in particular this combination has been shown
to reduce mortality and vascular events in
patients with T2DM [12].
As roughly 30% of hypertensive patients
have diabetes mellitus and 40% of newly
diagnosed diabetic patients are hypertensive,
the challenges associated with treating
hypertension in diabetic patients are
encountered regularly in general practice
[2, 13]. The Perindopril Plus Indapamide
Combination Blood Pressure Reduction
(PICASSO) trial (No. of the Ethics Committee
Approval: ETT-TUKEB-NIT 8-348/2009-
1018EKU-866/PI/09) was designed to provide
data that are directly relevant to everyday
medical practice. It is an open-label,
observational trial that included 9,257 patients
with uncontrolled hypertension despite
treatment. The trail evaluated blood pressure
after patients were switched to treatment with
fixed-dose perindopril 10 mg/indapamide
2.5 mg for 3 months [14]. In this subgroup
analysis of the PICASSO trial, the blood
pressure data in patients with T2DM or pre-
diabetes were analyzed to determine if
perindopril 10 mg/indapamide 2.5 mg should
be considered regularly for the treatment of
hypertension in diabetic patients.
MATERIALS AND METHODS
A retrospective analysis of the data from the
PICASSO trial was performed on the subgroup
of 2,762 patients with T2DM or pre-diabetes.
Other risk factors, such as age, dyslipidemia,
obesity, family history of early cardiovascular
diseases and smoking, were also recorded.
Patients with T2DM were defined as those
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meeting the criteria of the European guidelines
(fasting plasma glucose [7.0 mmol/L or 2-h
plasma glucose test [11.1 mmol/L) [15].
Patients with pre-diabetes were defined as
those with impaired fasting glucose (fasting
plasma glucose of 6.1–6.9 mmol/L and a 2-h
plasma glucose \7.8 mmol/L) or impaired
glucose tolerance (fasting plasma glucose \7.0
mmol/L but a 2-h plasma glucose [7.8 and
\11.1 mmol/L). Materials, methods, and results
of PICASSO have been described elsewhere [14].
Briefly, the PICASSO study was a 3-month,
open-label, observational, study which was
conducted between January 27 and August 31,
2010. The study comprised of 9,257 outpatients
who had uncontrolled hypertension; blood
pressure values above target levels defined by
the physician (71.0%), variability in blood
pressure measurements (22.6%), and poor
treatment tolerability (6.4%), despite ongoing
antihypertensive treatment; who had
fluctuating blood pressure; or who were
experiencing side effects with previous
treatment, were given a fixed-dose
combination of perindopril 10 mg/indapamide
2.5 mg (Coverex AS Komb Forte, EGIS
Pharmaceuticals Plc, Budapest, Hungary) for
3 months [16]. Grades of hypertension were
defined according to recent 2013 ESH/ESC
Guidelines [3]. To mimic real-life practice,
patients were only included if treatment with
perindopril/indapamide was in line with
previously established therapeutic plans;
therefore, exclusion criteria were not defined.
Additional antihypertensive treatments (alpha-
1-antagonist, beta-blocker, calcium channel
blocker, centrally acting agent) could be
maintained or added at the physician’s
discretion.
Office blood pressure and heart rate were
measured at baseline, 1 month, and 3 months
using validated oscillometric manometers.
Blood pressure control rates for diabetic
patients were defined according to the 2013
ESH/ESC guidelines as an office systolic blood
pressure (SBP)/diastolic blood pressure (DBP)
\140/85 mmHg [17]. Blood pressure control
rates for patients with pre-diabetes were
defined as office SBP/DBP \140/90 mmHg.
Baseline office blood pressure values of
patients previously treated with ACE
inhibitor ± hydrochlorothiazide (HCTZ)
(n = 1,778), angiotensin receptor blocker
(ARB) ± HCTZ (n = 240), enalapril ? HCTZ
(n = 203) or ramipril ? HCTZ (n = 31) were
compared to those values obtained during
perindopril/indapamide treatment.
Ambulatory blood pressure monitoring
(ABPM) was performed using a validated
device (MEDITECH ABPM, Budapest, Hungary)
in a subset of 93 patients. These patients were
selected based on the presence of additional
comorbidities, which prompted physicians to
compare results with office blood pressure. The
results of blood pressure and heart rate (HR) for
24 h, daytime (0600–2200 hours) and nighttime
(2200–0600 hours) were recorded at baseline,
1 month, and 3 months. In this subset, baseline
ambulatory blood pressure values of patients
previously treated with ACE inhibitor ± HCTZ
(n = 67), ARB ± HCTZ (n = 10) or
enalapril ? HCTZ (n = 8) were compared to
those values obtained during perindopril/
indapamide treatment.
Laboratory parameters [fasting plasma
glucose, serum total cholesterol, high-density
lipoprotein-cholesterol (HDL-C), low-density
lipoprotein-cholesterol (LDL-C), triglycerides,
potassium, creatinine, and uric acid] were
measured by routine laboratory methods at
baseline and 3 months when deemed
necessary by the treating physician.
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Tolerability and safety of treatment with
perindopril/indapamide were assessed by
recording the number of patient
complaints and possible side effects of
drugs at all visits.
All patients had been given written
information on this trial and gave informed
consent. The study was approved by the Central
Ethics Committee of Medical Research Council
(TUKEB of ETT) of Hungary.
The analysis in this article is based on
previously conducted studies, and does not
involve any new studies of human or
animal subjects performed by any of the
authors.
Statistics
Descriptive statistics were used to summarize
data. Between-group comparisons were
performed using one-sample t tests and Chi-
squared tests to compare baseline to treatment
data. Baseline characteristics were summarized
as mean ± standard deviations (SD) for
continuous variables and numbers of patients
and percentages for categorical variables, and
analyses were performed on an intention-to-
treat basis. Mean changes in office blood
pressure were analyzed according to the
grade of hypertension and pre-existing
antihypertensive treatment (ACE
inhibitor ? HCTZ, ARB ? HCTZ). A paired
t test was used to assess whether changes in
office- or ABPM-assessed SBP and DBP from
baseline to 3 months were significant. The
level of two-sided significance was set at 5%
(a = 0.05). Data were collected and analyzed in
accordance with the European Guidelines for
Good Clinical Practice/ICH guidelines. Clinical
and laboratory data were analyzed by an
independent statistical institute (Planimeter
Kft.; Budapest).
RESULTS
Of the 9,257 patients included in the PICASSO
final analysis population, 2,762 patients had
type 2 diabetes mellitus (n = 1,887) or pre-
diabetes (n = 875).
Mean age was 63.9 ± 10.6 years and 55.2% of
patients were female (Table 1). Waist
circumference was 106.2 ± 13.4 cm in males
and 101.9 ± 13.8 cm in females. Dyslipidemia
was recorded in 65.5% of patients, obesity [body
mass index (BMI) [30 kg/m2] in 64.9% of
patients, left ventricular hypertrophy in 37.5%
of patients, and microalbuminuria in 13.5% of
patients (Table 1).
Mean duration of hypertension was
12.2 ± 7.7 years. Ninety-six percent of patients
were being treated for hypertension at baseline.
Baseline SBP/DBP was 159.3 ± 14.7/
92.8 ± 9.7 mmHg and baseline heart rate was
79.5 ± 9.9 beats per minute (BPM). The
distribution of patients according to baseline
severity was high-normal blood pressure (3.0%;
n = 83), grade 1 hypertension (34.7%; n = 959),
grade 2 hypertension (48.9%; n = 1,350), and
grade 3 hypertension (13.4%; n = 370). No
patients were at blood pressure target at
enrollment.
At baseline, 33.3% of patients were
taking a diuretic: 28.7% were taking a
diuretic other than indapamide and 4.6%
were taking indapamide. With treatment
with perindopril/indapamide, the
percentage of patients taking other
antihypertensive therapies decreased from
63.0% to 62.5% for beta-blockers, 28.7% to
1.2% for diuretics other than indapamide,
48.7% to 40.1% for calcium channel
blockers, 8.7% to 1.0% for ARB ± HCTZ,
and increased from 7.2% to 9.6% for other
antihypertensive medications due to a 2.3%
increase in rilmenidine. When HCTZ use
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was considered in monotherapy and in
combination, the percent HCTZ use
decreased from 20.3% to 0.9%.
Blood Pressure After 3 Months
of Treatment with Perindopril/
Indapamide
Mean office SBP/DBP decreased over time to
139.6 ± 11.8/83.6 ± 7.6 mmHg after 1 month
and to 132.3 ± 9.7/80.1 ± 6.4 mmHg after
3 months (Fig. 1a). Changes from baseline to
3 months were statistically significant
(-27.0 ± 14.8/-12.7 ± 9.8 mmHg; p\0.001).
After 3 months of treatment, blood pressure
control was reached in 61% of patients.
Decreases in SBP and DBP were statistically
significant regardless of the grade of
hypertension at baseline (p\0.01). Between
baseline and 3 months, blood pressure
decreased by -4.2 ± 10.1/-2.2 ± 7.3 mmHg in
patients with high-normal blood pressure,
-19.2 ± 10.0/-9.4 ± 7.9 mmHg in patients
with grade 1 hypertension, -29.2 ± 10.9/
Table 1 Baseline characteristics in the enrolled
population: diabetes subgroup analysis of the PICASSO




Age (years), mean ± SD 63.9 ± 10.6
Abdominal circumference in males (cm),
mean ± SD
106.2 ± 13.4
Abdominal circumference in females
(cm), mean ± SD
101.9 ± 13.8
Risk factors, n (%)





Family history of early hypertensiona 1,114 (40.3)
Smoking 655 (23.7)
Associated disorders, n (%)
Coronary heart disease 1,022 (37.0)
Cerebrovascular event 410 (14.8)
Peripheral artery disease 362 (13.1)
Heart failure 274 (9.9)
Renal disease 204 (7.4)
Subclinical organ damage, n (%)
Left ventricular hypertrophyb 1,036 (37.5)
Atherosclerosis 935 (33.9)
Microalbuminuriac 372 (13.5)
Elevated serum creatinine leveld 235 (8.5)
Grade of hypertensione
High–normal 83 (3.0)
Grade 1 959 (34.7)
Grade 2 1,350 (48.9)
Grade 3 370 (13.4)
Previous antihypertensive therapy, n (%)




Calcium channel blocker 1,345 (48.7)
Diuretic 919 (33.3)
Angiotensin receptor blocker ± HCTZ 240 (8.7)
Other 199 (7.2)
HCTZ hydrochlorothiazide, SD standard deviation
a Males\55 years, females\65 years
b Left ventricular hypertrophy conﬁrmed by
electrocardiogram or electrocardiography
c Urinary albumin excretion of 30–300 mg/day
d 115–133 lmol/L in males and 107–124 lmol/L in
females
e Grade of hypertension was deﬁned according to the
2007 European Society of Hypertension/European Society
of Cardiology guidelines [29]
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-13.3 ± 8.7 mmHg in patients with grade 2
hypertension, and -45.1 ± 15.4/-21.5 ±
11.2 mmHg in patients with grade 3
hypertension.
Office blood pressure decreased significantly
in patients previously treated by a RAS
inhibitor ± HCTZ (n = 1,991), from
159.5 ± 14.7/92.5 ± 9.7 to 132.3 ± 9.8/
80.0 ± 6.3 mmHg (p\0.001). The decrease in
office blood pressure was similar for patients
previously on ACE inhibitors ± HCTZ or on
ARB ± HCTZ (both p\0.001) (Fig. 1b).
Ninety-three patients underwent ambulatory
blood pressure monitoring. In this subgroup, a
Fig. 1 a Change in ofﬁce blood pressure (n = 2,762) after
3 months of treatment with ﬁxed-dose combination of
perindopril 10 mg/indapamide 2.5 mg: diabetes subgroup
analysis of the PICASSO trial. b Ofﬁce blood pressure
according to previous treatment. ACEI angiotensin-
converting enzyme inhibitor, ARB angiotensin receptor
blocker, DBP diastolic blood pressure, HCTZ
hydrochlorothiazide, NS not signiﬁcant, SBP systolic blood
pressure, SD standard deviation
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higher percentage of comorbidities was
recorded as compared to that of the main
cohort (data not shown). Mean SBP/DBP in
this cohort decreased from 159.9 ± 16.2/
95.7 ± 9.5 to 130.4 ± 9.8/80.3 ± 6.2 mmHg
after 3 months. Changes from baseline to
3 months were statistically significant
(-29.5 ± 17.6/-15.4 ± 9.5 mmHg; p\0.001;
Fig. 2a, b). Mean daytime, nighttime, and 24-h
blood pressure as well as mean 24-h pulse
pressure, mean arterial pressure, and mean
24-h heart rate decreased significantly over the
course of the 3 months of treatment (p\0.001;
Fig. 2a, b). In patients previously treated with
ACE inhibitor ± HCTZ (n = 67) or ARB ± HCTZ
(n = 10), mean 24-h blood pressure decreased
by 23.4 ± 13.9/11.5 ± 9.7 and 22.3 ± 8.7/
10.4 ± 13.2 mmHg, respectively (p\0.001)
(Fig. 2c).
Tolerability and Safety after 3 Months
of Treatment with Perindopril/
Indapamide
Treatment was well tolerated. Thirty-six drug-
related adverse events occurred. Ankle edema
occurred in 11 patients (0.4% of patients) and
was reported most frequently, followed by
dizziness (n = 7; 0.3% of patients), and cough
(n = 6; 0.2% of patients). Seven serious adverse
events occurred, none of which was treatment
related: death of unspecified cause (n = 2),
transient ischemic attack (n = 2), aorta stenosis
diagnosed during study (n = 1), and worsening
congestive heart failure (n = 2).
Between baseline and 3 months, mean
changes in laboratory parameters were
significant for total cholesterol (-0.7 ±
0.9 mmol/L), LDL-C (-0.4 ± 0.7 mmol/L),
triglycerides (-0.4 ± 1.3 mmol/L), serum uric
acid (-18.2 ± 62.9 lmol/L), fasting blood
glucose (-0.6 ± 1.0 mmol/L), and serum
creatinine by (-3.9 ± 14.1 lmol/L) (for all
p\0.001, uric acid p = 0.004, serum creatinine
p = 0.04; Fig. 3). Changes were not significant
for serum potassium (-0.04 ± 0.4 mmol/L), and
HDL-C (?0.05 ± 0.3 mmol/L). These results
were obtained against a background of stable
concomitant treatment, including statins,
aspirin, and antidiabetics (Table 2).
DISCUSSION
The PICASSO study was designed to provide
physicians with data that are directly relevant to
daily medical practice and to the challenges
associated with treating hypertension. In this
T2DM subgroup analysis, we analyzed blood
pressure data in patients with T2DM or pre-
diabetes to determine if perindopril 10 mg/
indapamide 2.5 mg may offer an efficacious
and well-tolerated alternative to previous
unsuccessful antihypertensive treatments.
Overall, these patients constitute a difficult-to-
treat cohort in which 65% of patients were
obese and 62% of patients had grade 2 or 3
hypertension despite ongoing treatment.
Significant decreases in office blood pressure
and ambulatory blood pressure were noted after
3 months of treatment and 69% of patients
reached blood pressure control. As in the full
PICASSO trial, treatment was well tolerated and
was associated with improvements in laboratory
parameters.
In this study, significant decreases in office
blood pressure occurred regardless of baseline
blood pressure: -19.2/9.4 mmHg in patients
with grade 1 hypertension and -45.1/
21.5 mmHg in patients with grade 3
hypertension. As decreases in SBP of 10 mmHg
are associated with reductions in risk of
diabetes-related complications (-12%),
diabetes-related deaths (-15%), and
myocardial infarction (-11%) [18], these data
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suggest that treatment with perindopril/
indapamide would have a clinically
meaningful long-term impact.
Ambulatory SBP and pulse pressure are
independent predictors of cardiovascular
risk [19, 20] and blood pressure variability
over the course of a day has significant
impact on target organ damage and
cardiovascular risk in hypertensive patients
[21, 22]. The combination of perindopril/
indapamide has been shown to smooth the
blood pressure curve and indapamide in
monotherapy has previously been shown
to reduce 24-h SBP variability [7, 23]. In
this study, significant reductions in 24-h
blood pressure, daytime blood pressure,
nighttime blood pressure, 24-h pulse
pressure, and 24-h mean arterial pressure
occurred after 3 months of treatment with
perindopril/indapamide. A longer-term
study in a real-life setting would be
needed to determine the effects on organ
damage and cardiovascular risk.
For diabetic patients, treatment with ACE
inhibitors is recommended due to
their proven cardioprotective and
nephroprotective effects. This
recommendation was recently confirmed
once again in a meta-analysis [24].
Combination with diuretics may help
counterbalance the salt-retaining effects of
diabetes and inhibit compensatory feedback
loops. Within these therapeutic classes,
careful choice of antihypertensive treatment
is essential as drugs have different efficacy
and tolerability profiles due to differences in
molecular structure, pharmacokinetics, and
pharmacodynamics. The British Society of
Hypertension, for example, has recently
highlighted the fact that diuretics differ
greatly among themselves by recommending
that indapamide or chlorthalidone be
prescribed rather than HCTZ, which is
associated with significantly poorer
outcomes and an increased risk of mortality
[25]. Furthermore, decreases in blood
pressure presented herein support treatment
with combination of perindopril/indapamide
and the recommendation for combination
therapy.
Thiazide diuretics, due to their unwanted
effects on carbohydrate, lipid uric acid, and
electrolyte metabolism, are no longer the
preferred choice for treatment of hypertensive
patients with T2DM or pre-diabetes [25, 26].
Indapamide, however, is a thiazide-like
sulfonamide and has been shown to be
metabolically neutral in a wide range of
patients including diabetic ones [11, 27, 28].
In this study, metabolic neutrality of
indapamide is reflected in the improvement of
total cholesterol, fasting glucose, and
triglyceride levels that were obtained without
any changes of other concomitant treatment
with lipid lowering agents, or with
antidiabetics. This is likely to be due to a
decrease in dysmetabolic effects after
discontinuation of treatments such as HCTZ or
beta-blockers, e.g., atenolol. The lack of effect of
treatment on serum potassium levels may
reflect the fact that perindopril and
indapamide have opposing action on
potassium metabolism: ACE inhibitors may
increase while thiazides-type diuretics decrease
the plasma level of potassium by opposing
action on renal excretion.
Fig. 2 a, b Change in ambulatory blood pressure (n = 93)
after 3 months of treatment with ﬁxed-dose combination of
perindopril 10 mg/indapamide 2.5 mg: diabetes subgroup
analysis of the PICASSO trial. c Ambulatory blood
pressure according to previous treatment. ACEI
angiotensin-converting enzyme inhibitor, ARB angiotensin
receptor blocker, DBP diastolic blood pressure, HCTZ
hydrochlorothiazide, NS not signiﬁcant, SBP systolic blood
pressure, SD standard deviation
c
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Study Limitations
The overall decrease in blood pressure observed
in this trial was similar to the one observed in
the whole cohort (-27/-13 mmHg) [14]. The
blood pressure reduction data noted herein
needs to be considered in the context of real-
life everyday practice rather than that of
randomized controlled studies, and need to be
interpreted with the knowledge that the data
most likely include some degree of placebo
effect. To reflect real-life practice, specific
criteria were not predefined for enrollment in
the ambulatory blood pressure monitoring
substudy, and as a result, the patients had, on
average, more comorbidities than those in the
whole cohort. These data should not be
extrapolated to the whole cohort. Among
limitations it has to be mentioned that no
data were obtained for the duration of T2DM.
CONCLUSIONS
The PICASSO study was designed to provide
physicians with data that are directly relevant to
daily medical practice and to the challenges
associated with treating hypertension. The data
from this T2DM subgroup analysis of the main
data of PICASSO study suggest that perindopril
Fig. 3 Change in metabolic parameters that are most
frequently affected by some antihypertensive drugs, after
3 months of treatment with ﬁxed-dose combination of
perindopril 10 mg/indapamide 2.5 mg: diabetes subgroup
analysis of the PICASSO trial. Metabolic markers were
measured at the physician’s discretion. Means ± standard
deviation are presented. HDL-C high-density lipoprotein-
cholesterol, LDL-C low-density lipoprotein-cholesterol, NS
not signiﬁcant
Table 2 Concomitant treatments: diabetes subgroup
analysis of the PICASSO trial (n = 2,762)
Co-prescriptions, n (%) Baseline (%) 3 Months (%)
Statin 2,049 (74.2) 2,029 (73.5)
Acetylsalicylic acid 1,643 (59.5) 1,606 (58.1)
Oral antidiabetic 1,541 (55.8) 1,490 (53.9)
Insulin 366 (13.3) 343 (12.4)
Clopidogrel 214 (7.7) 210 (7.6)
Fibrate 182 (6.6) 180 (6.5)
Other 544 (19.7) 477 (17.3)
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10 mg/indapamide 2.5 mg may offer an
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